Savara (SVRA) announced the FDA has filed for review the BLA for Molbreevi as a therapy to treat patients with autoimmune PAP. The FDA granted Priority Review with a PDUFA action date of August 22.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
- Savara Enters New Material Definitive Agreement and Obligation
- Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
- Savara Highlights Autoimmune PAP Burden in Updated Presentation
- Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating